Inclusion Criteria:

- Patient age ≥ 18 yrs,

- Performance Status OMS < 2,

- Initially treated for Epithelial Ovarian Carcinoma

- Patient with only peritoneal relapse occurred at least 6 month from the initial
treatment, resectable without distant metastasis (with the exception of
communicating pleura effusion, sensitive to platine-based second line chemotherapy
and resectable lymph-nodes in the groin or retro peritoneal)

- Platinum based second-line chemotherapy before surgery with either
carboplatine-paclitaxel, or carboplatine-caelyx

- Complete cytoreductive surgery

- The surgery has to be planned 5 to 8 weeks from the last 2nd of chemotherapy

- No hepatic failure, bilirubin ≤ 1,5 time the Normal limit, ASAT et ALAT ≤ 3 time the
Upper Normal Limit,

- No Renal insufficiency (serum creatinine < 1,5 time the normal limit, creatinine
clearance >60 ml/min). calculated with MDRD method

- Hematology function : PNN ≥1,5x109/L, platelets ≥ 100x109/L,

- No contraindication to general anaesthesia for heavy surgery

- Patients having read, signed and dated Informed consent before any study procedure

- childbearing patients have to take appropriate contraceptive methods during the
treatment and until 6 months after the treatment

Exclusion Criteria:

- Patient age <18 years

- Previous cancer in the last 5 years (except cutaneous baso-cellular epithelioma or
uterine peripheral epithelioma)

- Hypersensitivity to Platinum compound

- Distant metastasis

- Use of anti-angiogenic treatment,

- Patient with other concurrent severe life threatening disease

- The need to perform more than two segmental digestive resections during the CRS +/-
HIPEC surgery

- Any progressive disease during the IV systemic second-line chemotherapy
(platine-based)

- Incomplete cytoreductive surgery with macroscopical residual disease (Sugarbaker>CC1)

- Early relapse: less than 6 mois after the end of the first treatment.

- Ovarian tumor other than Epithelioma Ovarian Cancer

- Uncontrolled infection,

- Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule,

- Clinically significant cardiovascular disease contraindicating the hyper hydratation,
which is necessary for HIPEC,

- Patient already treated with HIPEC for the ovarian cancer

- Individual deprived of liberty or placed under the authority of a tutor.